Framework for the Provision of Parenteral Systemic Anti-Cancer Therapies and Other Biologicals Including Immunotherapies

This Framework agreement is for the provision of Parenteral Systemic Anti-Cancer Therapies and Other Biologicals Including Immunotherapies initially for patients of East Midlands Pharmacy Collaborative (EMPC) Member Trusts referred to henceforth as the ‘Service’ to Participating Purchasing Authorities

This Tender will review the use of Parenteral Chemotherapy (plus associated therapies) and for Parenteral Biologics Inc. Immunotherapies within the East Midlands and look to provide a cost/service improvement through an Open Tender process. This contract outlines the provision of a dispensing/compounding and delivery service to patients’ homes for Parenteral Chemotherapy plus associated treatments and for Parenteral Biologics plus nursing support where required, for administration for all products. The Supplier must provide a comprehensive Homecare service for provision of Parenteral Chemotherapy plus associated treatments and for Parenteral Biologics Inc. Immunotherapies for the member Purchasing Authority’s in accordance with the agreed contract and legal requirements which comprises: (i) Compounding, dispensing, delivery and administration of Parenteral Chemotherapy plus associated supportive medicines and for Parenteral Biologics in a syringe or infusion bag or administration device (approved by an individual Purchasing Authority or collectively via all participating Purchasing Authority’s) with provision of a nurse to administer all doses. (ii) Pharma Funded schemes, where covered by the general service descriptor, will fall under this tender for the service element until such time a Nationally Agreed service specification for Pharma schemes is approved and adopted by both Pharma and the NHS. (iii) Unlicensed Imported medicines are subject to a locally signed technical agreement for the provision of the product and the provision of such products are not covered by this tender. (iv) For unlicensed medicines, the Purchasing Authority will stipulate the specific brand and product details to the Supplier. (v) Notwithstanding the above point regarding unlicensed imported medicines, where the Purchasing Authority chooses to use such product, the service element of this contract and all obligations around provision of that service are specifically covered in this specification and should be included in any resulting agreement. Additional information: This Framework agreement may extend to all National Health Service (NHS) bodies in England, including but not limited to: The Purchasing Collaborative Organisations that are listed under The Specialist Pharmacy Service may participate in this Framework during the Contract period. Please see the current list at: https://www.sps.nhs.uk/articles/collaborative-purchasing-organisations/ (https://www.sps.nhs.uk/articles/collaborative-purchasing-organisations/) NHS Provider Directory: https://www.england.nhs.uk/publication/nhs-provider-directory/ (https://www.england.nhs.uk/publication/nhs-provider-directory/) NHS Foundation Trusts at: https://www.england.nhs.uk/wp- content/uploads/2019/04/Public_Registry_FT_directory_190403.xls

The value of this Framework may increase during the 4 year period depending on Contract take up by the members listed in this Contract Notice